Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia. Psychiatric Quarterly 2009, 80: 241-249. PMID: 19768543, DOI: 10.1007/s11126-009-9111-9.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsInjectable risperidoneLong-Acting Injectable RisperidoneDuration of pharmacotherapyOral conventional antipsychoticsHalf of patientsMultivariable logistic regressionTreatment of schizophreniaDuration of treatmentProportional hazards modelOral antipsychoticsTreatment discontinuationOral medicationsReal-world practiceConventional antipsychoticsPatient characteristicsMedication adherenceAntipsychotic medicationVA patientsHazards modelAntipsychoticsMedicationsPatientsLogistic regressionRisperidone